Pure PDGF-BB Safety Data Sets New Bar for Regenerative Aesthetics

A newly published review by Michael Gold, MD, founder and medical director of Gold Skin Care Center in Nashville, Tennessee, synthesizes 2 recent peer-reviewed articles on recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and makes a pointed argument to the aesthetic medicine field: The 3-decade safety portfolio behind pure PDGF-BB should serve as the evidence benchmark against which all regenerative products are measured.

The review highlights 2 articles—"Safety of Exogenous Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) for Medical and Cosmetic Applications: A Review" and "Safety of up to 140 Daily Applications of Recombinant Human Platelet-Derived Growth Factor (rhPDGF-BB) onto Skin Wounds: Unboxing the Evidence"—and contextualizes their findings within what Gold describes as a rapidly expanding but underregulated regenerative aesthetics market.^2,3

MORE ON AESTHETICS

A Crowded Market, an Evidence Gap

The regenerative aesthetics space has grown substantially in recent years, driven by patient demand for treatments that improve skin quality, texture, and firmness through biological mechanisms rather than temporary volumization. Unlike fillers, bioregenerative agents aim to stimulate the body's own repair pathways, promoting collagen, elastin, and natural hyaluronic acid production over time for results that proponents describe as more sustained and structurally meaningful.

But Gold argues the market's rapid growth has outpaced its regulatory scaffolding. Many available products claiming regenerative capacity have not undergone the kind of systematic nonclinical pharmacokinetic, toxicology, or long-term clinical safety evaluation that regulators typically require for drug approval.

"The regenerative aesthetics space is moving faster than the evidence, and that creates real risk for patients and providers alike. What makes pure PDGF-BB stand out is not just what it does but how thoroughly it has been studied. Thirty years of nonclinical and clinical data across tens of thousands of subjects is not something you see often in this field, and it should be the benchmark we hold every regenerative product to going forward."
—Michael Gold, MD

What the Safety Record Shows

As Gold's review details, pure rhPDGF-BB is the active pharmaceutical ingredient in 4 FDA-approved products for chronic wound care and soft tissue and bone regeneration. The 2 reviewed articles draw on a research history spanning 3 decades, encompassing a wide range of administration routes—topical, injectable, and implantable—as well as dose levels frequently orders of magnitude higher than those used in aesthetic practice.

Pharmacokinetic data summarized in the review indicate that exogenously administered PDGF-BB functions locally, with a short half-life and minimal systemic exposure, even at high doses, in both animal and human studies. Skin irritation, hypersensitivity, and toxicity evaluations across multiple preclinical models found no significant adverse reactions regardless of delivery route, including subcutaneous, intradermal, intramuscular, intraperitoneal, and intravenous administration. Reproductive toxicity studies in rats receiving daily intravenous injections of the compound over 21 days of gestation reported no treatment-related mortality or meaningful adverse outcomes.

The clinical data reviewed are similarly extensive. Findings from more than 100 randomized controlled trials conducted over 25-plus years, involving upwards of 15,000 subjects, showed comparable adverse event rates between PDGF-treated patients and controls.

Resolving the Cancer Question

Among the most clinically significant findings Gold highlights is the resolution of a long-standing debate over PDGF's potential role in oncogenesis. The FDA had previously required a boxed warning on pure PDGF-BB products addressing theoretical cancer risk. As detailed in one of the reviewed articles, that warning was subsequently removed following long-term, retrospective, propensity-matched analyses comparing more than 13,000 patients who received up to 140 daily applications of topical PDGF-BB against untreated controls, with more than a decade of follow-up. The studies found no increased incidence of cancer or cancer-related mortality associated with pure PDGF-BB treatment.

"The safety portfolio for pure PDGF-BB—including the removal of the boxed cancer warning after long-term, propensity-matched follow-up in over 13,000 patients—gives providers a level of confidence that is simply not available for most regenerative products currently on the market."
—Michael Gold, MD

A Call for Field-Wide Standards

The broader argument Gold advances is that the aesthetic and wound care fields need to hold all regenerative products to a comparable evidence standard before widespread clinical adoption. The database established for pure PDGF-BB—spanning nonclinical models, randomized controlled trials, long-term follow-up studies, and regulatory review—represents the kind of foundation that should be expected, not exceptional.

For dermatologists and aesthetic providers making treatment decisions in a market with uneven evidence quality, Gold's review offers a practical takeaway: The availability of a well-characterized safety profile on a regenerative agent is itself a clinical differentiator worth weighing.

References

1. Gold MH, Keaney TC, Fitzgerald R. Setting the standard for peer-reviewed published studies on regenerative products in aesthetic medicine and post-procedure wound care. J Cosmet Dermatol. 2026;25(5):e70877. doi:10.1111/jocd.70877
2. Hee CK, Slade HB, Lynch SE. Safety of exogenous recombinant human platelet-derived growth factor-BB (rhPDGF-BB) for medical and cosmetic applications: a review. J Cosmet Dermatol. 2026;25(1):e70636. doi:10.1111/jocd.70636
3. Slade HB, Lynch SE, Dickerson JE Jr. Safety of up to 140 daily applications of recombinant human platelet-derived growth factor (rhPDGF-BB) onto skin wounds: unboxing the evidence. Wound Repair Regen. 2025;33(6):e70108. doi:10.1111/wrr.70108